image sourced from original article at Novo Nordisk reported that a higher 7.2 milligram dose of semaglutide, the active ingredient in Wegovy, led to significantly greater weight loss in adults with obesity who did not have type 2 diabetes. The findings come from the Step Up clinical trial, which followed participants for 72 weeks.
Patients receiving the 7.2 milligram dose lost an average of about 21 percent of their body weight, compared with 17.5 percent for those on the standard 2.4 milligram dose and 2.4 percent for those given a placebo. Among certain early responders taking the higher dose, average weight loss reached nearly 27.7 percent after about a year and a half.
The company said that approximately 84 percent of the weight lost with the higher dose came from fat rather than lean mass, while muscle function was preserved. The results suggest that increasing the dosage may enhance outcomes for some patients seeking significant weight reduction.
